Skip to content

Released Aug 8, 2019, after the close

10-Q filed Aug 8, 2019, 39 days after period end · 0001564590-19-030746

Q2 2019 · 10-Q
Revenue$67.00K−85.5% vs Q2 2018−98.2% vs Q1 2019
Net Income-$13.20MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.74N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$13,652,000N/M
Operating Cash Flowderived-$12,070,000N/M
Free Cash Flowderived-$12,157,000—
Margins · derived
Operating margin-20376.1%−18222.6 pt vs Q2 2018
Net margin-19701.5%−17551.2 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Revenue$67.00K$463.00K$249.00K—
Net Income-$13.20M-$9.96M-$9.17M-$6.06M
EPS Diluted-$0.74-$0.69-$36.21-$25.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR